Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study difficulty is more serious than expected. The budget isn't enough.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to Comparison clinical efficiency with IPFI patients who treated by different protocols(empirical therapy or preemptive therapy) in ICU.
a multicenter study ( a total of 2411 person-time ) found In the United States in 205, antifungal therapy in empirical therapy, preemptive therapy, target therapy of respectively 44%, 43%, 12%. While the existing on preemptive therapy and empiric treatment comparative study shows, the survival rate of the patients without differences, cost and application of antifungal drugs are relatively more in empirical therapy. These findings of differences, is due to the different research forecast model, treatment options vary widely, and are without a prospective multicenter study of verification. Initiation of antifungal therapy time and antifungal drug of choice is affected by many factors, including the risk stratification of patients, clinical manifestations, bacterial infection of evidence and non interventional diagnosis method results. How to grasp the opportunity to treat the fungal infections by empirical therapy or preemptive therapy that has plagued the global clinical doctors. The purpose of this study is aimed at the large scale prospective, multicenter study method to China, severe invasive pulmonary fungal infection of the empiric treatment with preemptive therapy for clinical contrast research, exploration of fungal treatment time and plan, to establish China's own optimal antifungal treatment options, are reduced in patients with severe fungal infection harm and increase the rate of successful treatment with evidence-based medical evidence.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| empirical therapy | immediate initiation of antifungal therapy; Itraconazole :1-14day,ivï¼›(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid) | ||
| preemptive therapy | Dynamic monitoring of fungal infection, initiation antifungal therapy when clinical diagnosis ( microbial + experiment +, G/GM, CT typical change ) approveled in two weeks Itraconazole :1-14day,iv;(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid) If within two weeks without obtaining positive results, researchers determine whether initiation of antifungal therapy。 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
suspected Pulmonary invasive fungal Infection in ICU patients with Mechanical Ventilation
Not provided
| Name | Affiliation | Role |
|---|---|---|
| yan kang, director | West China Hospital | Principal Investigator |
| xiao bo huang, director | Sichuan Provincial People's Hospital | Study Director |
| chuan zhang, director | Third people's Hospital of Chengdu City | Study Director |
| di-fen wang, director | Affiliated Hospital of Guiyang Medical College | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Affiliated Hospital of Guiyang Medical College | Guiyang | Guizhou | 550004 | China | ||
| Third people's Hospital of Chengdu City |
Not provided
Not provided
Not provided
Not provided
| Chengdu |
| Sichuan |
| 610031 |
| China |
| West China Hospital | Chengdu | Sichuan | 610041 | China |
| Sichuan provincial people's hospital | Chengdu | Sichuan | 610071 | China |